Subtype
Bone Neoplasm
CI-CAN-00000569Explore in graph →
Non-malignant65 active trials4 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000569Explore in graph →
Clinical trials
342 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | active not recruiting | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT03295981 | Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | recruiting | Phase 3 | 120 | St. Louis UniversityOTHER | 3 | Apr 22, 2026 | clinicaltrials |
| NCT05115331 | Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease(1-2 PUNCH) | active not recruiting | Phase 3 | 168 | University of CincinnatiOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02923011 | Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas | recruiting | Phase 3 | 56 | Matthew BucknorOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06669013 | Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas(FollowTheDIN) | recruiting | Phase 3 | 40 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05813665 | A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | not yet recruiting | Phase 3 | 146 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 29, 2026source: clinicaltrials